Tannic acid facilitates expression of the polypyrimidine tract binding protein and alleviates deleterious inclusion of CHRNA1 exon P3A due to an hnRNP H-disrupting mutation in congenital myasthenic syndrome

Human Molecular Genetics

Volumn 18, Issue 7, 2009, Pages 1229-1237

  Bian, Yang ^a   Masuda, Akio ^a   Matsuura, Tohru ^a   Ito, Mikako ^a   Okushin, Kazuya ^a   Engel, Andrew G ^b   Ohno, Kinji ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN H; POLYPYRIMIDINE TRACT BINDING PROTEIN; TANNIN; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ANIMAL CELL; ARTICLE; CONCENTRATION RESPONSE; CONGENITAL MYASTHENIC SYNDROME; CONTROLLED STUDY; DNA FLANKING REGION; DOSE RESPONSE; DRUG SYNTHESIS; GENE DELETION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; INTRON; MOUSE; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN TARGETING; RNA SPLICING; RNA TRANSLATION; TRANSCRIPTION INITIATION SITE;

BASE SEQUENCE; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; EXONS; HETEROGENEOUS-NUCLEAR RIBONUCLEOPROTEIN GROUP F-H; HETEROGENEOUS-NUCLEAR RIBONUCLEOPROTEINS; HUMANS; INTRONS; LUCIFERASES; MOLECULAR SEQUENCE DATA; MUTATION; MYASTHENIC SYNDROMES, CONGENITAL; POLYPYRIMIDINE TRACT-BINDING PROTEIN; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; RECEPTORS, NICOTINIC; RNA SPLICE SITES; RNA SPLICING; SEQUENCE DELETION; TANNINS;

EID: 63149091662     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddp023     Document Type: Article

References (62)

1. Hagerman, A.E. (2002) Tannin Chemistry. http://www.users.muohio.edu/ hagermae/.
2. Hamilton-Miller, J.M. (1995) Antimicrobial properties of tea ( Camellia sinensis L.). Antimicrob. Agents Chemother., 39, 2375-2377.
3. Yam, T.S., Hamilton-Miller, J.M. and Shah, S. (1998) The effect of a component of tea (Camellia sinensis) on methicillin resistance, PBP2' synthesis, and beta-lactamase production in Staphylococcus aureus. J. Antimicrob. Chemother., 42, 211-216.
4. Cozzolino, D., Cynkar, W.U., Dambergs, R.G., Mercurio, M.D. and Smith, P.A. (2008) Measurement of condensed tannins and dry matter in red grape homogenates using near infrared spectroscopy and partial least squares. J. Agric. Food Chem., 56, 7631-7636.
5. Wagner, E.J. and Garcia-Blanco, M.A. (2001) Polypyrimidine tract binding protein antagonizes exon definition. Mol. Cell. Biol., 21, 3281-3288.
6. Spellman, R. and Smith, C.W. (2006) Novel modes of splicing repression by PTB. Trends Biochem. Sci., 31, 73-76.
7. Kim, Y.K., Hahm, B. and Jang, S.K. (2000) Polypyrimidine tract-binding protein inhibits translation of bip mRNA. J. Mol. Biol., 304 119-133.
8. Moreira, A., Takagaki, Y., Brackenridge, S., Wollerton, M., Manley, J.L. and Proudfoot, N.J. (1998) The upstream sequence element of the C2 complement poly(A) signal activates mRNA 30 end formation by two distinct mechanisms. Genes Dev., 12, 2522-2534.
9. Cote, C.A., Gautreau, D., Denegre, J.M., Kress, T.L., Terry, N.A. and Mowry, K.L. (1999) A Xenopus protein related to hnRNP I has a role in cytoplasmic RNA localization. Mol. Cell, 4, 431-437.
10. Fred, R.G. and Welsh, N. (2008) The importance of RNA binding proteins in preproinsulin mRNA stability. Mol. Cell. Endocrinol. [Epub (doi:10.1016/j.mce.2008.06.007)].
11. Oberstrass, F.C., Auweter, S.D., Erat, M., Hargous, Y., Henning, A., Wenter, P., Reymond, L., Amir-Ahmady, B., Pitsch, S., Black, D.L. et al. (2005) Structure of PTB bound to RNA: Specific binding and implications for splicing regulation. Science, 309, 2054-2057.
12. Lin, C.H. and Patton, J.G. (1995) Regulation of alternative 30 splice selection by constitutive splicing factors. RNA, 1, 234-245.
13. Singh, R., Valcarcel, J. and Green, M.R. (1995) Distinct binding specificities and functions of higher eukaryotic polypyrimidine tract-binding proteins. Science, 268, 1173-1176.
14. Ashiya, M. and Grabowski, P.J. (1997) A neuron-specific splicing switch mediated by an array of pre-mRNA repressor sites: Evidence of a regulatory role for the polypyrimidine tract binding protein and a brain-specific PTB counterpart. RNA, 3, 996-1015.
15. Sauliere, J., Sureau, A., Expert-Bezancon, A. and Marie, J. (2006) The polypyrimidine tract binding protein (PTB) represses splicing of exon 6B from the beta-tropomyosin pre-mRNA by directly interfering with the binding of the U2AF65 subunit. Mol. Cell. Biol., 26, 8755-8769.
16. Amir-Ahmady, B., Boutz, P.L., Markovtsov, V., Phillips, M.L. and Black, D.L. (2005) Exon repression by polypyrimidine tract binding protein. RNA, 11, 699-716.
17. Chan, R.C. and Black, D.L. (1997) The polypyrimidine tract binding protein binds upstream of neural cell-specific c-src exon N1 to repress the splicing of the intron downstream. Mol. Cell. Biol., 17, 4667-4676.
18. Charlet, B.N., Logan, P., Singh, G. and Cooper, T.A. (2002) Dynamic antagonism between ETR-3 and PTB regulates cell type-specific alternative splicing. Mol. Cell, 9, 649-658.
19. Southby, J., Gooding, C. and Smith, C.W. (1999) Polypyrimidine tract binding protein functions as a repressor to regulate alternative splicing of alpha-actinin mutually exclusive exons. Mol. Cell. Biol. 19, 2699-2711.
20. Sharma, S., Kohlstaedt, L.A., Damianov, A., Rio, D.C. and Black, D.L. (2008) Polypyrimidine tract binding protein controls the transition from exon definition to an intron defined spliceosome. Nat. Struct. Mol. Biol., 15, 183-191.
21. Masuda, A., Shen, X.-M., Ito, M., Matsuura, T., Engel, A.G. and Ohno, K. (2008) hnRNP H enhances skipping of a nonfunctional exon P3A in CHRNA1 and a mutation disrupting its binding causes congenital myasthenic syndrome. Hum. Mol. Genet., 17, 4022-4035.
22. Beeson, D., Morris, A., Vincent, A. and Newsom-Davis, J. (1990) The human muscle nicotinic acetylcholine receptor alpha-subunit exist as two isoforms: A novel exon. EMBO J., 9, 2101-2106.
23. Newland, C.F., Beeson, D., Vincent, A. and Newsom-Davis, J. (1995) Functional and non-functional isoforms of the human muscle acetylcholine receptor. J. Physiol., 489, 767-778.
24. Krull, M., Petrusma, M., Makalowski, W., Brosius, J. and Schmitz, J. (2007) Functional persistence of exonized mammalian-wide interspersed repeat elements (MIRs). Genome Res., 17, 1139-1145.
25. Kielkopf, C.L., Lucke, S. and Green, M.R. (2004) U2AF homology motifs: protein recognition in the RRM world. Genes Dev., 18, 1513-1526.
26. Clery, A., Blatter, M. and Allain, F.H. (2008) RNA recognition motifs: boring? Not quite. Curr. Opin. Struct. Biol., 18, 290-298.
27. Markovtsov, V., Nikolic, J.M., Goldman, J.A., Turck, C.W., Chou, M.Y. and Black, D.L. (2000) Cooperative assembly of an hnRNP complex induced by a tissue-specific homolog of polypyrimidine tract binding protein. Mol. Cell. Biol., 20, 7463-7479.
28. Heemskerk, J., Tobin, A.J. and Ravina, B. (2002) From chemical to drug: neurodegeneration drug screening and the ethics of clinical trials. Nat. Neurosci., 5 (suppl.), 1027-1029.
29. Abbott, A. (2002) Neurologists strike gold in drug screen effort. Nature, 417, 109.
30. Piccioni, F., Roman, B.R., Fischbeck, K.H. and Taylor, J.P. (2004) A screen for drugs that protect against the cytotoxicity of polyglutamine-expanded androgen receptor. Hum. Mol. Genet., 13 437-446.
31. Rothstein, J.D., Patel, S., Regan, M.R., Haenggeli, C., Huang, Y.H., Bergles, D.E., Jin, L., Dykes Hoberg, M., Vidensky, S., Chung, D.S. et al. (2005) Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature, 433, 73-77.
32. Yu, P.B., Hong, C.C., Sachidanandan, C., Babitt, J.L., Deng, D.Y., Hoyng, S.A., Lin, H.Y., Bloch, K.D. and Peterson, R.T. (2008) Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism. Nat. Chem. Biol., 4, 33-41.
33. Slaugenhaupt, S.A., Mull, J., Leyne, M., Cuajungco, M.P., Gill, S.P., Hims, M.M., Quintero, F., Axelrod, F.B. and Gusella, J.F. (2004) Rescue of a human mRNA splicing defect by the plant cytokinin kinetin. Hum. Mol. Genet., 13, 429-436.
34. Anderson, S.L., Qiu, J. and Rubin, B.Y. (2003) EGCG corrects aberrant splicing of IKAP mRNA in cells from patients with familial dysautonomia. Biochem. Biophys. Res. Commun., 310, 627-633.
35. Brichta, L., Hofmann, Y., Hahnen, E., Siebzehnrubl, F.A., Raschke, H., Blumcke, I., Eyupoglu, I.Y. and Wirth, B. (2003) Valproic acid increases the SMN2 protein level: A well-known drug as a potential therapy for spinal muscular atrophy. Hum. Mol. Genet., 12, 2481-2489.
36. Brichta, L., Holker, I., Haug, K., Klockgether, T. and Wirth, B. (2006) In vivo activation of SMN in spinal muscular atrophy carriers and patients treated with valproate. Ann. Neurol., 59, 970-975.
37. Gottlicher, M., Minucci, S., Zhu, P., Kramer, O.H., Schimpf, A., Giavara, S., Sleeman, J.P., Lo Coco, F., Nervi, C., Pelicci, P.G. et al. (2001) Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J., 20, 6969-6978.
38. Chung, K.T., Wong, T.Y., Wei, C.I., Huang, Y.W. and Lin, Y. (1998) Tannins and human health: A review. Crit. Rev. Food Sci. Nutr., 38, 421-464.
39. Chen, C.N., Lin, C.P., Huang, K.K., Chen, W.C., Hsieh, H.P., Liang, P.H. and Hsu, J.T. (2005) Inhibition of SARS-CoV 3C-like protease activity by theaflavin-3,3′-digallate (TF3). Evid. Based Complement. Alternat. Med., 2, 209-215.
40. Sroka, Z., Rzadkowska-Bodalska, H. and Mazol, I. (1994) Antioxidative effect of extracts from Erodium cicutarium L. Z. Naturforsch. [C], 49, 881-884.
41. Gali, H.U., Perchellet, E.M., Klish, D.S., Johnson, J.M. and Perchellet, J.P. (1992) Hydrolyzable tannins: Potent inhibitors of hydroperoxide production and tumor promotion in mouse skin treated with 12-O-tetradecanoylphorbol-13-acetate in vivo. Int. J. Cancer, 51, 425-432.
42. Gali-Muhtasib, H.U., Yamout, S.Z. and Sidani, M.M. (2000) Tannins protect against skin tumor promotion induced by ultraviolet-B radiation in hairless mice. Nutr. Cancer, 37, 73-77.
43. Nepka, C., Sivridis, E., Antonoglou, O., Kortsaris, A., Georgellis, A., Taitzoglou, I., Hytiroglou, P., Papadimitriou, C., Zintzaras, I. and Kouretas, D. (1999) Chemopreventive activity of very low dose dietary tannic acid administration in hepatoma bearing C3H male mice. Cancer Lett., 141, 57-62.
44. Koide, T., Kamei, H., Hashimoto, Y., Kojima, T. and Hasegawa, M. (1999) Tannic acid raises survival rate of mice bearing syngeneic tumors. Cancer Biother. Radiopharm., 14, 231-234.
45. Nam, S., Smith, D.M. and Dou, Q.P. (2001) Tannic acid potently inhibits tumor cell proteasome activity, increases p27 and Bax expression, and induces G1 arrest and apoptosis. Cancer Epidemiol. Biomarkers Prev. 10, 1083-1088.
46. Taffetani, S., Ueno, Y., Meng, F., Venter, J., Francis, H., Glaser, S., Alpini, G. and Patel, T. (2005) Tannic acid inhibits cholangiocyte proliferation after bile duct ligation via a cyclic adenosine 5′,3′-monophosphate-dependent pathway. Am. J. Pathol., 166 1671-1679.
47. Chen, K.S., Hsiao, Y.C., Kuo, D.Y., Chou, M.C., Chu, S.C., Hsieh, Y.S. and Lin, T.H. (2008) Tannic acid-induced apoptosis and -enhanced sensitivity to arsenic trioxide in human leukemia HL-60 cells. Leuk. Res. [Epub (doi:10.1016/j.leukres.2008.08.006)].
48. Boyd, E.M., Bereczky, K. and Godi, I. (1965) The acute toxicity of tannic acid administered intragastrically. Can. Med. Assoc. J., 92, 1292-1297.
49. Dollahite, J.W., Pigeon, R.F. and Camp, B.J. (1962) The toxicity of gallic acid, pyrogallol, tannic acid, and Quercus havardi in the rabbit. Am. J. Vet. Res., 23, 1264-1267.
50. Barnes, D.G. and Dourson, M. (1988) Reference dose (RfD): Description and use in health risk assessments. Regul. Toxicol. Pharmacol., 8, 471-486.
51. Dourson, M.L., Felter, S.P. and Robinson, D. (1996) Evolution of science-based uncertainty factors in noncancer risk assessment. Regul. Toxicol. Pharmacol., 24, 108-120.
52. Foronda, N.M., Fowles, J., Smith, N., Taylor, M., Temple, W. and Darlington, C. (2007) The use of myocardial and testicular end points as a basis for estimating a proposed tolerable daily intake for sodium monofluoroacetate (1080). Regul. Toxicol. Pharmacol., 47, 29-36.
53. Afsana, K., Shiga, K., Ishizuka, S. and Hara, H. (2004) Reducing effect of ingesting tannic acid on the absorption of iron, but not of zinc, copper and manganese by rats. Biosci. Biotechnol. Biochem., 68 584-592.
54. Raponi, M., Buratti, E., Llorian, M., Stuani, C., Smith, C.W. and Baralle, D. (2008) Polypyrimidine tract binding protein regulates alternative splicing of an aberrant pseudoexon in NF1. FEBS J., 275, 6101-6108.
55. Venables, J.P. (2006) Unbalanced alternative splicing and its significance in cancer. Bioessays, 28, 378-386.
56. He, X., Pool, M., Darcy, K.M., Lim, S.B., Auersperg, N., Coon, J.S. and Beck, W.T. (2007) Knockdown of polypyrimidine tract-binding protein suppresses ovarian tumor cell growth and invasiveness in vitro. Oncogene, 26, 4961-4968.
57. Wang, C., Norton, J.T., Ghosh, S., Kim, J.J., Fushimi, K., Wu, J.Y., Stack, M.S. and Huang, S. (2008) PTB differentially affects malignancy in a cell line dependent manner. J. Biol. Chem., 283, 20277-20287.
58. Anwar, A., Ali, N., Tanveer, R. and Siddiqui, A. (2000) Demonstration of functional requirement of polypyrimidine tract-binding protein by SELEX RNA during hepatitis C virus internal ribosome entry site-mediated translation initiation. J. Biol. Chem., 275, 34231-34235.
59. Song, Y., Tzima, E., Ochs, K., Bassili, G., Trusheim, H., Linder, M., Preissner, K.T. and Niepmann, M. (2005) Evidence for an RNA chaperone function of polypyrimidine tract-binding protein in picornavirus translation. RNA, 11, 1809-1824.
60. Makeyev, E.V., Zhang, J., Carrasco, M.A. and Maniatis, T. (2007) The MicroRNA miR-124 promotes neuronal differentiation by triggering brain-specific alternative pre-mRNA splicing. Mol. Cell, 27, 435-448.
61. Ohno, K., Anlar, B., Özdirim, E., Brengman, J.M., DeBleecker, J.L. and Engel, A.G. (1998) Myasthenic syndromes in Turkish kinships due to mutations in the acetylcholine receptor. Ann. Neurol., 44, 234-241.
62. Masuda, A., Yoshikai, Y., Kume, H. and Matsuguchi, T. (2004) The interaction between GATA proteins and activator protein-1 promotes the transcription of IL-13 in mast cells. J. Immunol., 173, 5564-5573.